Table of Contents

Oxford Journals

Volume 23 Issue 5 May 2012

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.

editorial

Select this article
- K. Terada
DNA ploidy in endometrial cancer: unfinished business?
Ann Oncol (2012) 23(5): 1083-1084 first published online November 24, 2011 doi:10.1093/annonc/mdr549

reviews

Select this article
- Y. Loriot,
- C. Massard,
- and K. Fizazi
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases
Ann Oncol (2012) 23(5): 1085-1094 first published online January 20, 2012 doi:10.1093/annonc/mdr573
Select this article
- A. Herskovic,
- W. Russell,
- M. Liptay,
- M. J. Fidler,
- and M. Al-Sarraf
Esophageal carcinoma advances in treatment results for locally advanced disease: review
Ann Oncol (2012) 23(5): 1095-1103 first published online October 14, 2011 doi:10.1093/annonc/mdr433
Select this article
- P. Blinman,
- M. King,
- R. Norman,
- R. Viney,
- and M. R. Stockler
Preferences for cancer treatments: an overview of methods and applications in oncology
Ann Oncol (2012) 23(5): 1104-1110 first published online January 10, 2012 doi:10.1093/annonc/mdr559
Select this article
- M. Reck,
- F. Barlesi,
- L. Crinò,
- C. I. Henschke,
- D. Isla,
- S. Stiebeler,
- and D. R. Spigel
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
Ann Oncol (2012) 23(5): 1111-1120 first published online November 4, 2011 doi:10.1093/annonc/mdr463
OPEN ACCESS

original articles

breast cancer

Select this article
- P. Vici,
- M. Brandi,
- F. Giotta,
- P. Foggi,
- F. Schittulli,
- L. Di Lauro,
- N. Gebbia,
- B. Massidda,
- G. Filippelli,
- D. Giannarelli,
- A. Di Benedetto,
- M. Mottolese,
- G. Colucci,
- and M. Lopez
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study
Ann Oncol (2012) 23(5): 1121-1129 first published online September 28, 2011 doi:10.1093/annonc/mdr412
Select this article
- J. Cortes,
- V. Calvo,
- N. Ramírez-Merino,
- J. O'Shaughnessy,
- A. Brufsky,
- N. Robert,
- M. Vidal,
- E. Muñoz,
- J. Perez,
- S. Dawood,
- C. Saura,
- S. Di Cosimo,
- A. González-Martín,
- M. Bellet,
- O. E. Silva,
- D. Miles,
- A. Llombart,
- and J. Baselga
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
Ann Oncol (2012) 23(5): 1130-1137 first published online October 4, 2011 doi:10.1093/annonc/mdr432
Select this article
- B. Ejlertsen,
- J. Aldridge,
- K. V. Nielsen,
- M. M. Regan,
- K. L. Henriksen,
- A. E. Lykkesfeldt,
- S. Müller,
- R. D. Gelber,
- K. N. Price,
- B. B. Rasmussen,
- G. Viale,
- and H. Mouridsen
- for the Danish Breast Cancer Cooperative Group the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial
Ann Oncol (2012) 23(5): 1138-1144 first published online October 10, 2011 doi:10.1093/annonc/mdr438
Select this article
- A. Giordano,
- M. Giuliano,
- M. De Laurentiis,
- G. Arpino,
- S. Jackson,
- B. C. Handy,
- N. T. Ueno,
- E. Andreopoulou,
- R. H. Alvarez,
- V. Valero,
- S. De Placido,
- G. N. Hortobagyi,
- J. M. Reuben,
- and M. Cristofanilli
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy
Ann Oncol (2012) 23(5): 1144-1150 first published online September 28, 2011 doi:10.1093/annonc/mdr434
Select this article
- B. Bouvard,
- E. Hoppé,
- P. Soulié,
- M. Georgin-Mege,
- E. Jadaud,
- S. Abadie-Lacourtoisie,
- A. Petit Le Manac’h,
- A. Laffitte,
- R. Levasseur,
- M. Audran,
- D. Chappard,
- and E. Legrand
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy
Ann Oncol (2012) 23(5): 1151-1156 first published online September 7, 2011 doi:10.1093/annonc/mdr356
Select this article
- F. Rojo,
- J. García-Parra,
- S. Zazo,
- I. Tusquets,
- J. Ferrer-Lozano,
- S. Menendez,
- P. Eroles,
- C. Chamizo,
- S. Servitja,
- N. Ramírez-Merino,
- F. Lobo,
- B. Bellosillo,
- J. M. Corominas,
- J. Yelamos,
- S. Serrano,
- A. Lluch,
- A. Rovira,
- and J. Albanell
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Ann Oncol (2012) 23(5): 1156-1164 first published online September 9, 2011 doi:10.1093/annonc/mdr361
Select this article
- A. G. Pallis,
- I. Boukovinas,
- A. Ardavanis,
- I. Varthalitis,
- N. Malamos,
- V. Georgoulias,
- and D. Mavroudis
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
Ann Oncol (2012) 23(5): 1164-1169 first published online September 21, 2011 doi:10.1093/annonc/mdr405
Select this article
- J. M. Classe,
- S. Baffert,
- B. Sigal-Zafrani,
- M. Fall,
- C. Rousseau,
- S. Alran,
- P. Rouanet,
- C. Belichard,
- H. Mignotte,
- G. Ferron,
- F. Marchal,
- S. Giard,
- C. Tunon de Lara,
- G. Le Bouedec,
- J. Cuisenier,
- R. Werner,
- I. Raoust,
- J.-F. Rodier,
- F. Laki,
- P.-E. Colombo,
- S. Lasry,
- C. Faure,
- H. Charitansky,
- J.-B. Olivier,
- M.-P. Chauvet,
- E. Bussières,
- P. Gimbergues,
- B. Flipo,
- G. Houvenaeghel,
- F. Dravet,
- and A. Livartowski
Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients ‘on behalf of the Group of Surgeons from the French Unicancer Federation’
Ann Oncol (2012) 23(5): 1170-1177 first published online September 6, 2011 doi:10.1093/annonc/mdr355

gynecologic tumors

Select this article
- M. Pradhan,
- V. M. Abeler,
- H. E. Danielsen,
- B. Sandstad,
- C. G. Tropé,
- G. B. Kristensen,
- and B. Å. Risberg
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol (2012) 23(5): 1178-1184 first published online September 30, 2011 doi:10.1093/annonc/mdr368
OPEN ACCESS
Select this article
- L. Gladieff,
- A. Ferrero,
- G. De Rauglaudre,
- C. Brown,
- P. Vasey,
- A. Reinthaller,
- E. Pujade-Lauraine,
- N. Reed,
- D. Lorusso,
- S. Siena,
- H. Helland,
- L. Elit,
- and S. Mahner
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Ann Oncol (2012) 23(5): 1185-1189 first published online October 5, 2011 doi:10.1093/annonc/mdr441

gastrointestinal tumors

Select this article
- C. Twelves,
- W. Scheithauer,
- J. McKendrick,
- J.-F. Seitz,
- G. Van Hazel,
- A. Wong,
- E. Díaz-Rubio,
- F. Gilberg,
- and J. Cassidy
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
Ann Oncol (2012) 23(5): 1190-1197 first published online September 6, 2011 doi:10.1093/annonc/mdr366
Select this article
- J. W. Huh,
- Y. Y. Jeong,
- H. R. Kim,
- and Y. J. Kim
Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer
Ann Oncol (2012) 23(5): 1198-1206 first published online September 23, 2011 doi:10.1093/annonc/mdr404
Select this article
- F. Crea,
- L. Fornaro,
- E. Paolicchi,
- G. Masi,
- P. Frumento,
- F. Loupakis,
- L. Salvatore,
- C. Cremolini,
- M. Schirripa,
- F. Graziano,
- M. Ronzoni,
- V. Ricci,
- W. L. Farrar,
- A. Falcone,
- and R. Danesi
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
Ann Oncol (2012) 23(5): 1207-1213 first published online September 16, 2011 doi:10.1093/annonc/mdr387
Select this article
- J. M. Löhr,
- S. L. Haas,
- W.-O. Bechstein,
- G. Bodoky,
- K. Cwiertka,
- W. Fischbach,
- U. R. Fölsch,
- D. Jäger,
- D. Osinsky,
- J. Prausova,
- W. E. Schmidt,
- and M. P. Lutz
- CT4001 Study Group
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
Ann Oncol (2012) 23(5): 1214-1222 first published online September 6, 2011 doi:10.1093/annonc/mdr379

lung cancer

Select this article
- T. Brodowicz,
- T. Ciuleanu,
- J. Crawford,
- M. Filipits,
- J. R. Fischer,
- V. Georgoulias,
- C. Gridelli,
- F. R. Hirsch,
- J. Jassem,
- P. Kosmidis,
- M. Krzakowski,
- Ch. Manegold,
- J. L. Pujol,
- R. Stahel,
- N. Thatcher,
- J. Vansteenkiste,
- C. Minichsdorfer,
- S. Zöchbauer-Müller,
- R. Pirker,
- and C. C. Zielinski
- for the Central European Cooperative Oncology Group (CECOG)
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
Ann Oncol (2012) 23(5): 1223-1229 first published online September 22, 2011 doi:10.1093/annonc/mdr381
Select this article
- J. Clarey,
- S. C. Kao,
- S. J. Clarke,
- and J. Vardy
The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials
Ann Oncol (2012) 23(5): 1229-1233 first published online October 10, 2011 doi:10.1093/annonc/mdr443

urogenital tumors

Select this article
- M. D. Michaelson,
- J. Bellmunt,
- G. R. Hudes,
- S. Goel,
- R. J. Lee,
- P. W. Kantoff,
- C. A. Stein,
- P. Lardelli,
- I. Pardos,
- C. Kahatt,
- A. Nieto,
- M. Cullell-Young,
- N. L. Lewis,
- and M. R. Smith
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
Ann Oncol (2012) 23(5): 1234-1240 first published online September 19, 2011 doi:10.1093/annonc/mdr399
Select this article
- J. S. de Bono,
- L. R. Molife,
- G. Sonpavde,
- J. P. Maroto,
- E. Calvo,
- T. H. Cartwright,
- D. M. Loesch,
- K. Feit,
- A. Das,
- E. A. Zang,
- J. Wanders,
- S. Agoulnik,
- and D. P. Petrylak
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
Ann Oncol (2012) 23(5): 1241-1249 first published online September 7, 2011 doi:10.1093/annonc/mdr380
Select this article
- D. Kobayashi,
- O. Takahashi,
- T. Fukui,
- and P. P. Glasziou
Optimal prostate-specific antigen screening interval for prostate cancer
Ann Oncol (2012) 23(5): 1250-1253 first published online September 23, 2011 doi:10.1093/annonc/mdr413

hematologic malignancies

Select this article
- A. Fosså,
- I. H. Fiskvik,
- A. Kolstad,
- G. F. Lauritzsen,
- E. Aurlien,
- A. K. Blystad,
- K. H. Hole,
- I. M. Ikonomou,
- and H. Holte
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol (2012) 23(5): 1254-1259 first published online September 16, 2011 doi:10.1093/annonc/mdr385
Select this article
- B. A. Campbell,
- C. Hornby,
- J. Cunninghame,
- M. Burns,
- M. MacManus,
- G. Ryan,
- E. Lau,
- J. F. Seymour,
- and A. Wirth
Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy
Ann Oncol (2012) 23(5): 1259-1266 first published online October 6, 2011 doi:10.1093/annonc/mdr439
Select this article
- N. Schmitz,
- S. Zeynalova,
- B. Glass,
- U. Kaiser,
- E. Cavallin-Stahl,
- M. Wolf,
- M. Haenel,
- M. Loeffler,
- L. Truemper,
- and M. Pfreundschuh
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
Ann Oncol (2012) 23(5): 1267-1273 first published online October 11, 2011 doi:10.1093/annonc/mdr440
Select this article
- R. Alvarez,
- J. Dupuis,
- A. Plonquet,
- C. Christov,
- C. Copie-Bergman,
- F. Hemery,
- I. Gaillard,
- T. El Gnaoui,
- F. Kuhnowski,
- M. Bedoui,
- K. Belhadj,
- P. Brugières,
- and C. Haioun
Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma
Ann Oncol (2012) 23(5): 1274-1279 first published online September 30, 2011 doi:10.1093/annonc/mdr436
Select this article
- S. A. M. van de Schans,
- A. N. M. Wymenga,
- D. J. van Spronsen,
- H. C. Schouten,
- J. W. W. Coebergh,
- and M. L. G. Janssen-Heijnen
Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma
Ann Oncol (2012) 23(5): 1280-1286 first published online September 23, 2011 doi:10.1093/annonc/mdr411

head and neck cancer

Select this article
- B. B. Y. Ma,
- M. K. M. Kam,
- S. F. Leung,
- E. P. Hui,
- A. D. King,
- S. L. Chan,
- F. Mo,
- H. Loong,
- B. K. H. Yu,
- A. Ahuja,
- and A. T. C. Chan
A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
Ann Oncol (2012) 23(5): 1287-1292 first published online September 23, 2011 doi:10.1093/annonc/mdr401

oncology practice

Select this article
- B. W. Lamb,
- N. Sevdalis,
- C. Taylor,
- C. Vincent,
- and J. S. A. Green
Multidisciplinary team working across different tumour types: analysis of a national survey
Ann Oncol (2012) 23(5): 1293-1300 first published online October 19, 2011 doi:10.1093/annonc/mdr453

phase I and pharmacokinetics

Select this article
- C. A. Gomez-Roca,
- L. Lacroix,
- C. Massard,
- T. De Baere,
- F. Deschamps,
- R. Pramod,
- R. Bahleda,
- E. Deutsch,
- C. Bourgier,
- E. Angevin,
- V. Lazar,
- V. Ribrag,
- S. Koscielny,
- L. Chami,
- N. Lassau,
- C. Dromain,
- C. Robert,
- E. Routier,
- J. P. Armand,
- and J.-C. Soria
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
Ann Oncol (2012) 23(5): 1301-1306 first published online September 14, 2011 doi:10.1093/annonc/mdr383
Select this article
- H.-T. Arkenau,
- R. Plummer,
- L. R. Molife,
- D. Olmos,
- T. A. Yap,
- M. Squires,
- S. Lewis,
- V. Lock,
- M. Yule,
- J. Lyons,
- H. Calvert,
- and I. Judson
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
Ann Oncol (2012) 23(5): 1307-1313 first published online October 19, 2011 doi:10.1093/annonc/mdr451
Select this article
- J. Stebbing,
- A. Dalgleish,
- A. Gifford-Moore,
- A. Martin,
- C. Gleeson,
- G. Wilson,
- L. R. Brunet,
- J. Grange,
- and S. Mudan
An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma
Ann Oncol (2012) 23(5): 1314-1319 first published online September 19, 2011 doi:10.1093/annonc/mdr363

epidemiology

Select this article
- C. A. González,
- F. Megraud,
- A. Buissonniere,
- L. Lujan Barroso,
- A. Agudo,
- E. J. Duell,
- M. C. Boutron-Ruault,
- F. Clavel-Chapelon,
- D. Palli,
- V. Krogh,
- A. Mattiello,
- R. Tumino,
- C. Sacerdote,
- J. R. Quirós,
- E. Sanchez-Cantalejo,
- C. Navarro,
- A. Barricarte,
- M. Dorronsoro,
- K.-T. Khaw,
- N. Wareham,
- N. E. Allen,
- K. K. Tsilidis,
- H. Bas Bueno-de-Mesquita,
- S. M. Jeurnink,
- M. E. Numans,
- P. H. M. Peeters,
- P. Lagiou,
- E. Valanou,
- A. Trichopoulou,
- R. Kaaks,
- A. Lukanova-McGregor,
- M. M. Bergman,
- H. Boeing,
- J. Manjer,
- B. Lindkvist,
- R. Stenling,
- G. Hallmans,
- L. M. Mortensen,
- K. Overvad,
- A. Olsen,
- A. Tjonneland,
- K. Bakken,
- V. Dumeaux,
- E. Lund,
- M. Jenab,
- I. Romieu,
- D. Michaud,
- T. Mouw,
- F. Carneiro,
- C. Fenge,
- and E. Riboli
Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project
Ann Oncol (2012) 23(5): 1320-1324 first published online September 14, 2011 doi:10.1093/annonc/mdr384
Select this article
- C. Neppl-Huber,
- M. Zappa,
- J. W. Coebergh,
- E. Rapiti,
- J. Rachtan,
- B. Holleczek,
- S. Rosso,
- T. Aareleid,
- H. Brenner,
- and A. Gondos
- the EUNICE Survival Working Group
Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths
Ann Oncol (2012) 23(5): 1325-1334 first published online September 28, 2011 doi:10.1093/annonc/mdr414

sarcomas

Select this article
- A. G. Dumont,
- L. Rink,
- A. K. Godwin,
- M. Miettinen,
- H. Joensuu,
- J. R. Strosberg,
- A. Gronchi,
- C. L. Corless,
- D. Goldstein,
- B. P. Rubin,
- R. G. Maki,
- A. J. Lazar,
- D. Lev,
- J. C. Trent,
- and M. von Mehren
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients
Ann Oncol (2012) 23(5): 1335-1340 first published online October 12, 2011 doi:10.1093/annonc/mdr442

supportive care

Select this article
- F. Saad,
- J. E. Brown,
- C. Van Poznak,
- T. Ibrahim,
- S. M. Stemmer,
- A. T. Stopeck,
- I. J. Diel,
- S. Takahashi,
- N. Shore,
- D. H. Henry,
- C. H. Barrios,
- T. Facon,
- F. Senecal,
- K. Fizazi,
- L. Zhou,
- A. Daniels,
- P. Carrière,
- and R. Dansey
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Ann Oncol (2012) 23(5): 1341-1347 first published online October 10, 2011 doi:10.1093/annonc/mdr435
Select this article
- R. X. Zhang,
- X. J. Wu,
- D. S. Wan,
- Z. H. Lu,
- L. H. Kong,
- Z. Z. Pan,
- and G. Chen
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial
Ann Oncol (2012) 23(5): 1348-1353 first published online September 22, 2011 doi:10.1093/annonc/mdr400
Select this article
- A. Enblom,
- A. Johnsson,
- M. Hammar,
- E. Onelöv,
- G. Steineck,
- and S. Börjeson
Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea—a randomized controlled study
Ann Oncol (2012) 23(5): 1353-1361 first published online September 23, 2011 doi:10.1093/annonc/mdr402

cancer prevention

Select this article
- M. Inoue,
- N. Sawada,
- T. Matsuda,
- M. Iwasaki,
- S. Sasazuki,
- T. Shimazu,
- K. Shibuya,
- and S. Tsugane
Attributable causes of cancer in Japan in 2005—systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan
Ann Oncol (2012) 23(5): 1362-1369 first published online November 2, 2011 doi:10.1093/annonc/mdr437

letters to the editor

Select this article
- L. Fornaro,
- F. Crea,
- G. Masi,
- E. Paolicchi,
- F. Loupakis,
- F. Graziano,
- L. Salvatore,
- M. Ronzoni,
- V. Ricci,
- C. Cremolini,
- M. Schirripa,
- R. Danesi,
- and A. Falcone
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
Ann Oncol (2012) 23(5): 1370-1371 first published online March 1, 2012 doi:10.1093/annonc/mds031
Select this article
- M. Iorfida,
- S. Dellapasqua,
- V. Bagnardi,
- A. Cardillo,
- N. Rotmensz,
- M. G. Mastropasqua,
- L. Bottiglieri,
- A. Goldhirsch,
- G. Viale,
- and M. Colleoni
HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
Ann Oncol (2012) 23(5): 1371-1372 first published online March 12, 2012 doi:10.1093/annonc/mds064

Advance Access

May 1, 2012

Current Issue

May 2012 23 (5)

Published on behalf of

ESMO

The European Society for Medical Oncology

The Journal

Impact factor: 6.452

5-Yr impact factor: 5.660

Also affiliated with

Japanese Society of Medical Oncology

Editor-in-Chief

Professor Jan B. Vermorken

View full editorial board

For Authors

This journal enables compliance with the NIH Public Access Policy

Open access options available for authors - visit Oxford Open

Open access options available for authors - visit Oxford Open

Alerting Services

Corporate Services

Most

Online ISSN 1569-8041 - Print ISSN 0923-7534

Oxford Journals Oxford University Press

Other Oxford University Press sites:

Annals of Oncology

editorial

DNA ploidy in endometrial cancer: unfinished business?

reviews

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases

Esophageal carcinoma advances in treatment results for locally advanced disease: review

Preferences for cancer treatments: an overview of methods and applications in oncology

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

original articles

breast cancer

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer

Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients ‘on behalf of the Group of Surgeons from the French Unicancer Federation’

gynecologic tumors

Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

gastrointestinal tumors

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Prognostic value of preoperative radiological staging assessed by computed tomography in patients with nonmetastatic colon cancer

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

lung cancer

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials

urogenital tumors

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Optimal prostate-specific antigen screening interval for prostate cancer

hematologic malignancies

Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis

Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma

Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma

head and neck cancer

A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

oncology practice

Multidisciplinary team working across different tumour types: analysis of a national survey

phase I and pharmacokinetics

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma

epidemiology

Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project

Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths

sarcomas

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

supportive care

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial

Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea—a randomized controlled study